# OnCo record hiv-associated-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/hiv-associated-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "hiv-associated-lymphoma" ;
  schema:name "HIV-associated (AIDS-related) lymphomas"@en ;
  schema:alternateName "AIDS-related lymphoma"@en, "ARL"@en, "Primary effusion lymphoma"@en, "Plasmablastic lymphoma"@en, "HIV-associated Hodgkin lymphoma"@en ;
  schema:description "People living with HIV have a raised risk of aggressive lymphomas, driven by immune suppression and viruses such as Epstein-Barr virus. The transformation of the last two decades is that, with antiretroviral therapy continued through treatment, these lymphomas are treated with the same full-dose chemotherapy and antibody regimens as in anyone else, with similar chances of cure."@en ;
  schema:url <https://onco.cc/cancers/hiv-associated-lymphoma/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/AIDS-related_lymphoma> ;
  schema:citation <https://www.cancer.gov/types/lymphoma/patient/aids-related-treatment-pdq>, <https://doi.org/10.1182/blood-2009-08-231613>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480>, <https://amcoperations.com/> ;
  onco:tag "nci-coverage", "rare", "haematologic", "virus-associated" ;
  onco:related <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/burkitt-lymphoma/>, <https://onco.cc/cancers/primary-cns-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/kaposi-sarcoma/>, <https://onco.cc/cancers/post-transplant-lymphoproliferative-disorder/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/global-oncology-access/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/cd38/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/pomalidomide/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/> ;
  onco:pathways <https://onco.cc/pathways/oncogenic-viruses/>, <https://onco.cc/pathways/myc/>, <https://onco.cc/pathways/antigen-presentation-immunoediting/> ;
  onco:terms <https://onco.cc/terms/ebv-term/>, <https://onco.cc/terms/double-hit-lymphoma/>, <https://onco.cc/terms/cell-of-origin/>, <https://onco.cc/terms/intrathecal-therapy/>, <https://onco.cc/terms/hhv8-kshv/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-trial-diversity/>, <https://onco.cc/bottlenecks/b-global-access/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-sparano-blood/> ;
  onco:pipeline <https://onco.cc/technologies/car-t/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/pomalidomide/> ;
  onco:standardOfCare <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/technologies/g-csf-growth-factors/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/pomalidomide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/trials/bmt-ctn-0803/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/bleomycin/> .